Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

Join­ing hands with sev­er­al aca­d­e­m­ic and in­dus­try part­ners from the UK, Boehringer In­gel­heim is launch­ing a quest to de­vel­op a gene ther­a­py for cys­tic fi­bro­sis — one that, if suc­cess­ful, would shake up a field plagued by some re­cent fail­ures and dom­i­nat­ed by Ver­tex.

The back­bone of the col­lab­o­ra­tion is 17 years worth of work done by the UK Cys­tic Fi­bro­sis Gene Ther­a­py Con­sor­tium, pulling to­geth­er re­searchers from Im­pe­r­i­al Col­lege Lon­don and the Uni­ver­si­ties of Ox­ford and Ed­in­burgh. With help from Boehringer, the con­sor­tium will lead the de­vel­op­ment and com­ple­tion of pre­clin­i­cal stud­ies on a gene ther­a­py that it’s iden­ti­fied, to a point where the prod­uct will be ready for hu­man stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER